Retatrutide is a notable triple-agonist peptide, which means it targets three different hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon. These hormones play vital roles in regulating blood sugar, appetite, and energy expenditure, making Retatrutide a promising candidate for treating obesity and potentially type 2 diabetes mellitus.
